What is Measured in a BNP Assay
BNP assays measure multiple molecular forms of B-type natriuretic peptide, including the active BNP hormone (BNP 1-32), its precursor proBNP (1-108 amino acids), and the inactive N-terminal fragment NT-proBNP (1-76 amino acids), with significant cross-reactivity between these forms depending on the specific antibody epitopes used in each assay 1, 2.
The Molecular Forms Detected
The BNP assay does not measure a single, pure molecule. Instead, it detects a mixture of related peptides:
- Active BNP (BNP 1-32): The 32 amino acid biologically active hormone (amino acid residues 77-108 of the precursor)
- ProBNP (BNP 1-108): The 108 amino acid precursor molecule that splits into BNP and NT-proBNP
- NT-proBNP (amino acids 1-76): The inactive N-terminal fragment released when proBNP is cleaved
Research demonstrates that proBNP is actually the predominant form measured in most BNP assays, particularly in heart failure patients 3. The proBNP:BNP ratio in patient plasma averages 6.3 (ranging from 1.8 to 10.8), meaning the precursor form comprises the majority of what commercial BNP assays detect 3. High molecular weight BNP (approximately 37 kDa, consistent with proBNP) represents the major immunoreactive component, with a ratio of approximately 1.9:1 compared to the low molecular weight active BNP (approximately 4 kDa) 4.
Why This Cross-Reactivity Occurs
The cross-reactivity between these molecular forms stems from the antibody recognition sites used in commercial assays 1. For BNP measurement, assays typically use:
- One antibody binding to the ring structure of BNP
- A second antibody binding to either the carboxy-terminal or amino-terminal end
Since proBNP contains the complete BNP sequence plus the NT-proBNP sequence, antibodies designed to detect BNP will inevitably recognize proBNP as well 1. This is not a flaw but rather an inherent characteristic of sandwich immunoassays targeting these peptides.
Clinical Implications
The fact that commercial BNP assays measure predominantly proBNP rather than the active hormone has important clinical ramifications 5. ProBNP itself lacks biological activity and must be cleaved by specific plasma proteases to generate active BNP. In heart failure patients, this peripheral processing may be impaired, meaning a substantial portion of measured "BNP" may be biologically inactive precursor 5.
The molar concentration of NT-proBNP in patient plasma is approximately 10 times higher than proBNP, which itself is present at much higher concentrations than active BNP 3. This explains why NT-proBNP assays often show higher absolute values than BNP assays in the same patient.
Assay-Specific Variations
Different commercial BNP assays can yield results varying by 1.2- to 7.2-fold for the same sample due to differences in antibody epitope specificity 6. Guidelines emphasize that results should be reported in ng/L rather than pmol/L until clinically relevant molecules are clearly determined and reference systems are standardized 1.
Critical preanalytical factors affecting what is measured include:
- Sample type: EDTA plasma is required for BNP; serum or heparin plasma for NT-proBNP (EDTA gives 8-10% negative bias for NT-proBNP) 1
- Storage conditions: Samples should be collected in iced tubes and processed rapidly to prevent in vitro degradation 1
- Glycosylation and proteolytic cleavage: Both processes affect BNP recognition by antibodies and contribute to differences in stability between assays 1